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ABSTRACT 
Background/Objective: Pharmacists receive training on medications and point of care testing (POCT) 
devices. Physicians and pharmacists leverage collaborative practice agreements (CPAs) to define 
protocols by which pharmacists modify and optimize prescription medication therapy. In theory, this 
framework could be applied to international medical mission clinics. This study aimed to determine if a 
CPA enabling pharmacists to optimize medications based on H. pylori or malaria POCT results in 
evidence-based dispensing of antimicrobial and antimalarial medications in the medical mission trip 
setting. 
 
Methods: This IRB-approved, prospective study was conducted in four Ugandan villages from May 16-
22, 2017. Patients diagnosed at the clinic with gastritis, gastroesophageal reflux disease (GERD), peptic 
ulcer disease (PUD), or malaria were included. Individuals receiving H. pylori or malaria treatment prior 
to enrollment were excluded. A CPA was established between visiting pharmacists and Ugandan 
physicians describing allowances for pharmacist-led medication optimization. Patients were seen by a 
physician or nurse, received a preliminary prescription, referred for POCT, and provided informed 
consent. A pharmacist evaluated POCT results, optimized medications, and generated and dispensed a 
final prescription. Collected data included demographics, preliminary prescription, POCT result, and final 
prescription. 
 
Results: A total of 234 patients were included: 70 patients with H. pylori (85.7% females, mean age (±SD) 
48.1 ± 17.3 years) with 0 positive POCT results (0.0%); 164 patients with malaria (61.6% females, mean 
age (±SD) 13.8 ± 14.4 years) with 61 positive POCT results (37.2%). Of the 234 POCTs, 76.1% were 
ordered by physicians, 18.8% by pharmacists, and 5.1% by nurses. Of preliminary prescriptions, 78.6% 
requested pharmacy to dose. Final prescriptions were 42.7% optimized by pharmacists, 3.0% by 
physician or nurse, and 54.7% required no changes (includes preliminary prescriptions listed as 
pharmacy to dose). Overall, 97 per protocol changes were made prior to dispensing. After POCT, 
evidence-based diagnoses prevented the dispensing of ten antimicrobial prescriptions for H. pylori, and 
all 61 patients with positive malaria POCT results received appropriate weight-based treatment. 
 
Conclusion: Utilization of a CPA in the medical mission trip setting allowed for pharmacist-led POCT and 
medication optimization, resulting in evidence-based allocation of available antimicrobial and 
antimalarial medications. 
 
  
BACKGROUND 
On short-term medical mission trips, it is customary for patients to present to a mobile clinic and 
describe the symptoms of their ailment(s) to a physician. The physician will use the patient’s description 
of symptoms, a physical assessment, and his or her clinical judgement to make a diagnosis and prescribe 
treatment. What is often lacking, however, is the presence of diagnostic testing, which could be 
performed through the use of point-of-care testing (POCT) devices at remote clinics.  
 
Pharmacists have the potential to fulfill this unmet need because they are educated on how to 
appropriately use POCT devices and interpret the results. The value of pharmacy services in the medical 
mission trip setting was demonstrated by a 2011 study which found over 2,000 pharmacy interventions 
were provided for 1,149 patients. The most common interventions involved patient counseling, 
medication substitutions based on availability, and other pharmacotherapy recommendations. In a 
survey of team member satisfaction, over 97% strongly agreed that pharmacist contributions to the 
team were essential for the success of the trip and 100% strongly agreed they would like to see a 
pharmacist involved in future trips.1 Further evidence suggests that pharmacists’ knowledge of 
medications and their appropriate use, storage, and labeling is critical to the delivery of quality services 
in this setting.2 Furthermore, pharmacists’ knowledge of regulatory issues, patient counseling, and 
overall pharmacy organization and workflow is well-suited for the medical mission setting.3  
 
In the United States (U.S.), physicians and pharmacists leverage collaborative practice agreements 
(CPAs) to define protocols by which pharmacists can modify and optimize prescription drug therapy. A 
CPA is defined as a “formal agreement in which a licensed provider makes a diagnosis, supervises 
patient care, and refers patients to a pharmacist under a protocol that allows the pharmacist to perform 
specific patient care functions.”4 CPAs often contain evidence-based treatment protocols for a 
pharmacist to follow in making decisions about prescribing new medications post-diagnosis or modifying 
existing therapies.5 Utilization of CPAs in outpatient clinics and community pharmacies have 
demonstrated a significant improvement in patient outcomes.6 A 2010 systematic review and meta-
analysis found significant improvements in medication adherence, patient knowledge, and quality of life 
when pharmacists were involved in direct patient care. Therapeutic and safety outcomes, such as A1C, 
cholesterol, blood pressure, and medication adverse events were significantly reduced in patients seen 
by pharmacists over comparative services.6 The benefit of CPAs has also been demonstrated in acute 
conditions, such as streptococcal pharyngitis. In a 2016 study, pharmacists at 55 chain and independent 
community pharmacies performed POCT for streptococcal pharyngitis and provided treatment with 
antibiotics according to a CPA with a physician.7  
 
Commercially available, diagnostic POCT is available for Helicobacter pylori and malaria infections. H. 
pylori is a gram negative bacteria found in the stomach, and it is responsible for more than 90% of 
duodenal ulcers and up to 80% of gastric ulcers worldwide. H. pylori infection may present with 
symptoms of pain when the stomach is empty (i.e., between meals and early in the morning), nausea, 
vomiting, loss of appetite, and gastrointestinal bleeding.8 Malaria is a mosquito-borne disease caused by 
a parasite, and an estimated 3.2 billion people currently live an area where they are at risk of 
transmission.9 There are four species of parasite that mainly effect humans: Plasmodium falciparum, P. 
vivax, P. ovale, and P. malariae. Of these, P. falciparum is the most virulent species, and is the most 
common seen in Uganda. Symptoms of malaria infection include fever, chills, flu-like illness, mild 
anemia, and dehydration.10 
 There are a variety of approaches to the treatment of H. pylori infection. Acid suppressants, such as 
histamine-2 receptor antagonists and proton pump inhibitors, may help relieve symptoms and heal 
mucosal inflammation but do not treat the infection. Appropriate treatment also includes a combination 
of antibiotics; the antibiotic regimen and duration of therapy recommended varies depending on the 
guideline referenced. Further, the regional antibiotic resistance patterns and eradication rates are 
important factors to consider when selecting a treatment regimen. The American College of 
Gastroenterology describes two 3-drug regimens and one 4-drug regimen as first line therapies to select 
for a patient, all given for 10 to 14 days.11 Due to concerns for emerging resistance, a consensus 
statement was published in 2016 recommending a 4-drug regimen for 14 days as first-line therapy for all 
patients.12 An additional consideration for this study were the recommendations provided by the 
Ugandan Clinical Guidelines, which were last updated in 2012, and recommend a 3-drug regimen for 7 
to 14 days, depending on the choice of acid suppressant therapy.10 Table 1 outlines specific first-line 
recommendations for H. pylori management according to these three treatment guidelines. 
 
The treatment of malaria infections largely depends on disease severity, the species of parasite (if 
known), and the part of the world in which the infection was acquired. For this reason, this study 
referred to the recommendations of the Ugandan Clinical Guidelines. These guidelines emphasize the 
importance of counseling patients on sleeping under insecticide-treated bed nets. First-line 
pharmacologic therapy includes Coartem® (artemether/lumefantrine), unless a patient is a child less 
than four months of age or five kilograms or a pregnant woman in her first trimester. In these patients, 
oral quinine is the first line treatment choice, and is second-line in all other patients. Any other 
antimalarial medication that is recommended by the World Health Organization can also be considered 
as alternatives.10 
 
Collectively, the evidence on the benefit of CPAs has brought The Institute of Medicine to recognize the 
critical role played by pharmacists in the areas of medication safety and management, as well as the 
value of pharmacist-physician collaboration in patient care.13 Furthermore, training in collaborative care 
as members of interprofessional teams is a significant area of focus in the recently revised Accreditation 
Council for Pharmacy Education (ACPE) Standards for Doctor of Pharmacy (PharmD) Programs.14 This 
also provides rationale for including student pharmacists on medical mission trips, in addition to 
licensed pharmacists. 
 
In theory, pharmacists and student pharmacists could apply the framework of POCT and CPAs to the 
medical mission clinic setting outside of the U.S. to shift prescribing patterns from symptom-based to 
diagnosis-based treatment, and thus ensure appropriate allocation of scarce medical resources. There is 
little to no published literature that actually quantifies the impact pharmacists can have in preserving 
valuable healthcare resources in a medical mission setting. This study aims to fill this evidence gap, with 
the larger societal impact of promoting antimicrobial stewardship practices in order to combat 
resistance in areas of the world where these disease states are endemic. The objective of the this study 
is to determine if a CPA enabling pharmacists to optimize medications based on H. pylori or malaria 
POCT results enables evidence-based dispensing of antimicrobial and antimalarial medications in the 
medical mission trip setting.  
   
 
Guidelines Recommended Pharmacotherapy Duration 
American College of 
Gastroenterology11 
Standard-dose proton pump inhibitor twice daily 
Clarithromycin 500mg twice daily 
Amoxicillin 1000mg twice daily 
10-14 days 
Bismuth subsalicylate 525mg four times daily 
Metronidazole 250mg four times daily 
Tetracycline 500mg four times daily 
Ranitidine 150mg twice daily OR  
Standard-dose proton pump inhibitor twice daily 
Toronto Consensus 
Statement12 
Bismuth subsalicylate 525mg four times daily 
Metronidazole 500mg three to four times daily 
Tetracycline 500mg four times daily 
Standard-dose proton pump inhibitor twice daily 
14 days 
Uganda Clinical Guidelines10 
Amoxicillin 500mg three times daily 
Metronidazole 400mg three times daily 
Omeprazole 20mg twice daily 
7 days 
Amoxicillin 500mg three times daily 
Metronidazole 400mg three times daily 
Ranitidine 300mg once daily 
14 days 
Table 1. Guideline recommendations for first-line H. pylori treatment regimens 
 
METHODS  
A team of 5 U.S. pharmacists, a Ugandan pharmacist, 12 U.S. student pharmacists, a U.S. nurse, 3 
Ugandan nurses, 2 Ugandan physicians, and 4 other U.S. volunteers provided care at clinic sites in four 
remote villages in the Mukono District of Uganda (Ntenjeru, Mpunge, Lulagwe, and Bunakijja) over the 
course of one week, from May 16, 2017 through May 22, 2017. The clinic was available to any person 
presenting with any type of health complaint; however, only malaria or H. pylori cases were focused on 
in this research.  
 
Inclusion Criteria and Exclusion Criteria  
Patients presenting to the clinic were triaged by student pharmacists, and subjective information was 
collected. A Patient Intake Form was used to document demographics, past medical history, and vital 
signs. Each patient was then referred to the physician for clinical evaluation. Patients were identified as 
eligible for participation in this study if a suspected diagnosis of gastritis, gastroesophageal reflux 
disease (GERD), peptic ulcer disease (PUD), or malaria was documented on the Patient Intake Form. 
Patients of any age were eligible to participate. Individuals with a diagnosis of H. pylori or malaria prior 
to arriving at the clinic were excluded due to inability to accurately capture prior treatment regimens. H. 
pylori and malaria were selected for evaluation because they were among the most common disease 
states of patients seen in the clinic for evaluation in previous installments of this mission trip. In 
addition, these are disease states in which antibiotic dispensing could be tailored based upon POCT 
results.  
 
Informed Consent 
Any patient meeting the above inclusion criteria was read the informed consent statement, with the use 
of translators as necessary. Consent was documented with a signature or a fingerprint if the patient was 
unable to sign. If the patient was a minor, consent was obtained by his/her legal guardian. The research 
team member who obtained the informed consent also signed the form. Patients were informed of their 
ability to withdraw from the study at any time and were ensured they would receive the established 
standard treatment regardless of their participation in this study.  
 
Point-of-Care Testing (POCT) 
The clinic workflow is described in Figure 1. The physician could initially prescribe a treatment regimen 
prior to POCT (hereafter referred to as “preliminary prescription”) based on the chief complaint, 
presenting signs and symptoms of the patient, and physical exam. The POCT could have been ordered 
directly by the physician or the pharmacy personnel if other patients meeting inclusion criteria for this 
study were identified. In either case, a pharmacist or student pharmacist performed the POCT. Finger 
stick devices were used according to the methods outlined in the package inserts of the device. 
 
 
 
 
 
Collaborative Practice Protocol 
Under the CPA, the pharmacist could make pre-specified permitted medication changes for both H. 
pylori and malaria per the protocol outlined in Appendix I. All medication changes made by the 
pharmacist or pharmacy staff were documented and initialed by the person making the adjustment. Of 
note, a patient with a negative POCT result for malaria was referred back to the physician for further 
evaluation. Treatment for a positive H. pylori POCT result was stratified according to past medical 
history. Those with a history of H. pylori infection or prior use of any of the antibiotics in the treatment 
protocol were given a 4-drug regimen due to increased potential for resistance as recommended by the 
American College of Gastroenterology, Toronto Consensus Statement, and the Ugandan Clinical 
Guidelines.10-12 When multiple first-line options were appropriate, specific medications in the treatment 
protocols were selected based on medication availability at the clinic site.  
 
Data Analysis 
Data was de-identified and collected in Microsoft Excel. The primary objective of this study was to assess 
the impact of POCT results for patients with a suspected diagnosis of H. pylori and/or malaria on 
prescribing patterns for antibiotics or antimalarial medications. This was determined by tabulating the 
number of antibiotics or antimalarial medications that were not dispensed due to a negative POCT 
result. As a secondary objective, the number and types of modifications made by a pharmacist per the 
CPA protocol due to the POCT result was assessed. Statistical analyses were performed using Stata/SE 
(Version 15.0. College Station, Texas: StataCorp LLC). Paired t-tests were used to compare results before 
and after POCT.  
 
Figure 1. Clinic Workflow 
RESULTS 
Patient Population 
A total of 234 patients were enrolled in the study, 70 patients in the H. pylori group and 164 patients in 
the malaria group. Relevant baseline characteristics are shown in Table 2. 
 
 All 
N (%) 
H. pylori 
N (%) 
Malaria 
N (%) 
No. enrolled 234 (100.0) 70 (29.9) 164 (70.1) 
Gender 
Female 
Male 
 
161 (68.8) 
73 (31.2) 
 
60 (85.7) 
10 (14.3) 
 
101 (61.6) 
63 (38.4) 
Age, years 
(mean ± SD) 
22.4 ± 22.0 48.1 ± 17.3 13.8 ± 14.4 
Table 2. Baseline Characteristics 
 
Point-of-Care Testing 
POCT were primarily ordered by the physician (n=178, 76.1%), but pharmacists and nurses were also 
involved in identifying patients that qualified for enrollment in the study, and thus a diagnostic POCT. 
There were 44 patients identified for POCT by a pharmacist (18.8%), and 12 patients identified by a 
nurse (5.1%).  
 
The results of the POCT are depicted in Figure 2. No positive results were seen in the H. pylori group, 
while 61 positive results were seen in the malaria group.  
 
 
 
 
 
Medication Optimization 
Of the preliminary prescriptions written by the physician before the patient was referred for POCT, 
78.6% were written with ‘pharmacy to dose’. The remaining 21.4% had medication, dose, and duration 
written by the physician. Of the final prescriptions, 45.3% required optimization after POCT results were 
Figure 2. POCT Results 
available: 42.3% were optimized by a pharmacist per the CPA protocol, while the remaining 3.0% were 
optimized by a physician or nurse outside of the specifications of the protocol (Figure 3).  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The impact of the optimization performed after POCT results is demonstrated in Table 3. Medication 
optimization by a pharmacist prevented the dispensing of 10 antibiotic prescriptions. There was a 
statistically significant increase in the dispensing of acid suppressants for symptom management after 
POCT results (p < 0.001). In the malaria group, 100% of the 61 patients with a positive POCT result 
received antimalarial medications at an appropriate dose.  
 
 Before POCT 
N (%) 
After POCT 
N (%) 
p-value 
H. pylori 
Number of antibiotics: 
0 
1 
2 
 
61 (88.6) 
5 (7.1) 
3 (4.3) 
 
69 (98.6) 
1 (1.4) 
0 (0.0) 
p = 0.006 
Number of acid suppressants: 
0 
1 
2 
 
39 (55.7) 
28 (40.0) 
3 (4.3) 
 
6 (8.6) 
61 (87.1) 
3 (4.3) 
p < 0.001 
Malaria 
Appropriate dosing 14 (8.5) 61 (37.2) p < 0.001 
Table 3. Impact of POCT Results on Antibiotic and Antimalarial Dispensing 
 
 
 
Figure 3. Medication Optimization by Healthcare Professional 
The types of changes made by a pharmacist during medication optimization were quantified (Table 4). 
There were 97 changes made within the specifications of the CPA protocol, and 9 changes made outside 
of the protocol. The changes made outside of the protocol were requested or approved by the 
physician, and were primarily related to increasing the day supply of medications dispensed for 
symptom management for patients with a negative POCT result.  
  
 All 
N (%) 
H. pylori 
N (%) 
Malaria 
N (%) 
No change required 128 (54.7) 13 (18.6) 115 (70.1) 
Change per protocol 97 (41.5) 49 (70.0) 48 (29.3) 
Change by type: 
Medication Addition 
Medication Substitution 
Medication Deletion 
Day Supply 
 
79 (33.8) 
7 (3.0) 
7 (3.0) 
96 (41.0) 
 
32 (45.7) 
6 (8.6) 
6 (8.6) 
48 (68.6) 
 
47 (28.7) 
1 (0.6) 
1 (0.6) 
48 (29.3) 
Change outside of protocol  9 (3.8) 8 (11.4) 1 (0.6) 
Table 4. Types of Medication Optimization Performed by Pharmacists 
 
DISCUSSION 
The results of this study demonstrate that utilizing POCT to make treatment decisions based on a 
confirmed diagnosis and a CPA to allow medication optimization by pharmacists is not only possible, but 
a strategy that should be considered in the medical mission setting. There was a statistically significant 
reduction in unnecessary antimicrobial and antimalarial medication dispensing. Because there were no 
positive results for the H. pylori group, there should be no antibiotics dispensed unless an alternative 
diagnosis is noted; this occurred for one patient in the H. pylori cohort for which the physician felt an 
antibiotic was warranted given the patient’s full symptom presentation. In the malaria group, all 
patients with a POCT-confirmed diagnosis were able to receive appropriate weight-based therapy 
without having to return to the physician after POCT. This study emphasizes the ability of pharmacists to 
contribute to the global antimicrobial stewardship efforts. Through utilizing diagnosis-based treatment 
strategies, pharmacists were able to promote appropriate antibiotic prescribing. The importance of 
antimicrobial stewardship and the role that pharmacists can play in the effort to prevent the 
development of antimicrobial resistance across the world cannot be understated.  
  
Pharmacists were able to be integrated in the patient care process by performing the POCT for all 
patients, and using the results to inform pharmacotherapy decisions. The benefit of a pharmacist as a 
member of the healthcare team was further revealed in the number of modifications made to 
prescriptions prior to dispensing. Pharmacists optimized therapy through medication additions, 
substitutions, deletions, and day supply changes when necessary with very few changes requiring special 
permission from the physician. Further, the number of preliminary prescriptions that were written for 
pharmacy to dose indicates the trusting relationship built between physicians and pharmacists through 
establishing a CPA. In particular, this CPA bridged pharmacists from the U.S. and physicians from 
Uganda; the authors believe one contributing factor to this result was that collaborative relationships 
have been built over time through annual medical mission trips. This can demonstrate the impact of 
professional relationships to student pharmacists participating in this experience on an international 
level. 
 
There are some limitations to this study. Language and cultural barriers made it difficult to obtain a 
complete and thorough past medical history on some patients. In the medical mission setting, it is 
difficult to establish follow-up care to assess health outcomes, such as if the disease was appropriately 
treated or their symptoms were effectively managed with the prior care they received at local clinics. 
This study also did not utilize a control group to look at the difference in dispensing before and after the 
use of POCT was implemented at the clinic sites.  
 
This research could be further expanded by determining the impact of preventing the dispensing of 
unnecessary medications on cost savings in this setting. This is particularly crucial on medical mission 
trips, as they are primarily dependent on donated medications and have a limited formulary. This kind of 
analysis could justify the expense of POCT devices and supplies and tailor the formulary to include 
specific medications for the treatment of H. pylori and malaria. Further research may also assess the 
impact of pharmacist-led medication optimization on long-term health outcomes, particularly if the 
team returns to the same villages on a yearly basis.  
 
CONCLUSION 
Utilization of a CPA in the medical mission trip setting allowed for pharmacist-led POCT and medication 
optimization, resulting in evidence-based allocation of available antimicrobial and antimalarial 
medications.  
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APPENDIX. Collaborative Practice Agreement (CPA) Protocol  
Permitted Medication Changes for Malaria 
*A positive test will be defined as a reading of positive on the display of the POCT device 
1. Negative: Referral to MD 
2. Positive*: Coartem 20mg/120mg (dosing follows instructions and table below) 
_#_ tablet(s) STAT, then _#_ tablet(s) 8 hours following the initial dose, then _#_ tablet(s) twice daily 
for 2 days 
Weight  Age Administration Instructions Total Tablets 
≥5kg to <15kg ≤16 years 1 tablet  6 tablets 
≥15kg to <25kg ≤16 years 2 tablets 12 tablets 
≥25kg to <35kg ≤16 years 3 tablets 18 tablets 
>35kg >16 years 4 tablets 24 tablets 
 
Permitted Medication Changes for H. Pylori 
*A positive test will be defined as a reading of positive on the display of the POCT device 
ǂA significant PMH is defined as a history of H. pylori infection or prior use of any of the antibiotics in the 
H. pylori treatment protocol 
1. Negative: Any one of the following options prescribed for 7 days: 
ADULT CHILD 
Calcium carbonate 500mg 2 tabs BID PRN (28 tabs) Calcium carbonate 500mg 1 tab BID PRN (14 tabs) 
Ranitidine 150mg 1 tab BID (14 tabs) Ranitidine 5-10 mg/kg/day in 2 divided doses 
Omeprazole 20mg 1 cap QAM (7 caps) Omeprazole 20mg 1 capsule QAM (if >30kg) (7 caps) 
2. Positive*: Any one of the following options prescribed for 14 days: 
 ADULT 
PATIENT CLASSIFICATION REGIMEN 
Non-Significant PMH Omeprazole 20mg 1 capsule BID (28 capsules) 
Amoxicillin 500mg 2 capsules BID (56 capsules) 
Clarithromycin 500mg 1 tablet BID (28 capsules) 
Significant PMHǂ Omeprazole 20mg 1 capsule BID (28 capsules) 
Amoxicillin 500mg 2 capsules BID (56 capsules) 
Clarithromycin 500mg 1 tablet BID (28 capsules) 
Metronidazole 200 mg 2 tablets BID (56 capsules) 
Amoxicillin Allergy/Unavailable Omeprazole 20mg 1 capsule BID (28 capsules)  
Clarithromycin 500mg 1 tablet BID (56 capsules)  
Metronidazole 200mg 2 tablets TID (84 capsules) 
Clarithromycin Allergy/Unavailable Omeprazole 20mg 1 capsule BID (28 capsules)  
Amoxicillin 500mg 2 capsules BID (56 capsules)  
Metronidazole 200mg 2 tablets BID (56 capsules) 
Clarithromycin AND Metronidazole 
Allergy/Unavailable 
Omeprazole 20mg 1 capsule BID (28 capsules)  
Amoxicillin 500mg 2 capsules BID (56 capsules)  
Levofloxacin 500mg 1 tablet QD (14 tablets) 
  
 CHILD 
PATIENT CLASSIFICATION REGIMEN 
Non-Significant PMH Omeprazole 20mg BID (<30kg: refer to MD; ≥30 kg = 20mg) 
Amoxicillin 50 mg/kg/day divided BID (max daily dose 2,000mg) 
Clarithromycin 20 mg/kg/day divided Q12H (max single dose 500mg) 
Significant PMHǂ Omeprazole 20mg BID (<30kg: refer to MD; ≥30 kg = 20mg) 
Amoxicillin 50 mg/kg/day divided BID (max daily dose 2,000mg) 
Clarithromycin 20 mg/kg/day divided Q12H (max single dose 500mg) 
Metronidazole 20 mg/kg/day divided BID (max daily dose 1,000mg) 
 
